Our Vision

Provide chronic pain patients with an easy way to get relief without drugs or invasive surgeries.

Our mission is to provide 100,000 chronic pain patients per year with a better treatment option. We know that this is a momentous goal, equal to the number of patients receiving pain treatment utilizing today’s neuromodulation. By doubling the patients treated with neuromodulation we have a shot at reducing the dependence on opioids long term. To achieve this goal, our treatment option has to be fast and convenient, similar in the time required for a drug injection or needle-based nerve ablation, the two primary therapeutic interventions of the pain physician office. Our treatment option will be free of drug side effects such as addiction, to replace at least in part some of the millions of opioid prescriptions per year.

CEO Interview

Manfred Franke sat down with LSI to discuss Neuronoff’s vision to revolutionize the standard of care for millions of individuals suffering from chronic pain.

From Vision to Reality

The Injectrode platform is designed to simplify neuromodulation treatments, making them more accessible for chronic condition patients. Our strategy through 2027 covers three conditions, starting with chronic pain. Post FDA approval, Neuronoff aims to broaden Injectrode's application to additional innovative therapies. Ultimately, our goal is to offer an easier method for clinicians to stimulate nerves, providing a minimally invasive, non-pharmacological treatment option for various chronic conditions like overactive bladder and hypertension. Key milestones and the timeline are outlined below.

Pathway to Market by Indication

The Injectrode has advanced to Technology Readiness Level 7 (TRL 7), demonstrating its readiness for practical applications. This achievement is supported by comprehensive lab testing, preclinical work, and successful human clinical trials.

Neuromodulation Today

Neuromodulation therapies are used to treat various conditions, including chronic pain, Parkinson’s disease, overactive bladder, and epilepsy. While some patients experience relief, the current standard of care suffers from 3 key limitations.

  • • Procedure times ranging from 17 to 283 minutes
    • Large incisions (>1 cm), leaving scars
    •Wound care assistance from caregivers

  • • Hooks, tines, “S” loops for anchoring
    • Clinical expertise & intensive training required
    • Revision surgery to remove/replace migrated or fractured leads

  • • Prior payer approval
    • Patients must exhaust other treatment options
    • 5 years from onset until eligible for neuromodulation

Neuromodulation Tomorrow

Neuromodulation will be as easy as a drug injection. Placement and removal will be done by needle, removing the need for surgery, saving time, money, and the patient from scars.

  • • Needle-based delivery
    • No visible scars
    • No need to change wound dressings

  • • Self-anchoring leads
    • No specialized training or years of experience
    • As simple as a steroid injection

  • • Patients become eligible for neuromodulation after repeated steroid injections don’t provide adequate relief
    • Patients can try neuromodulation for 30 days. If they respond, they keep the device. Otherwise, the device is removed.
    • Optional addition of an implanted IPG for hands-free treatment

“There’s an opportunity for the Injectrode to be a gamechanger. This would simplify my workflow for PNS and DRG. With no bulky hardware, patients can maintain autonomy and get back to the activities they enjoy most.”

- Hesham Elsharkawy, MD, MBA

The Injectrode platform technology is anticipated to be used to treat many conditions. While our current focus is chronic pain, there is ongoing research and development in bladder and hypertension indications.

Applications

Chronic Pain

Patients often treat pain with pharmaceutical intervention. When over-the-counter options provide insufficient relief, opioids may be prescribed. The Injectrode could be a minimally invasive chronic pain treatment option offered in lieu of opioids, or used in conjunction with opioids until patients can be slowly weaned off these high-risk addictive treatment options.

Bladder

Overactive bladder and neurogenic bladder have been treated with neuromodulation approaches, and patients have expressed willingness to consider peripheral nerve stimulation as a treatment option. The Injectrode’s minimally invasive nature may address the limitations of existing therapies.

Hypertension & Heart Failure

Baroreceptor stimulation has been shown to be a promising approach for hypertension and heart failure treatment. Preliminary data suggests that the Injectrode could be a viable treatment option.

Future Applications

The fundamental technology of the Injectrode has many potential applications beyond our current applications of focus. To see some of the indications and nerve targets we are exploring, head to our applications page.